Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression signature of EpCAMlow/PDPN+ and EpCAMhigh/PDPN- cancer cells in engineered human NSCLC HSAEC_4T53RD mouse xenograft model.

ABSTRACT: Gene expression signature of EpCAMlow/PDPN+ and EpCAMhigh/PDPN- cancer cells in engineered human NSCLC HSAEC_4T53RD mouse xenograft model.

ORGANISM(S): Homo sapiens

PROVIDER: GSE209983 | GEO | 2022/08/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression signature of EpCAMlow/PDPN+ and EpCAMhigh/PDPN- cancer cells in engineered human NSCLC HSAEC_4T53RD mouse xenograft model.

Project description:Gene expression signature of EpCAMlow/PDPN+ and EpCAMhigh/PDPN- cancer cells in engineered human NSCLC HSAEC_4T53RD mouse xenograft model.

| PRJNA863271 | ENA

Gene expression in WT and podoplanin (PDPN)-deficient MEFs

Project description:MEFs were grown from WT and PDPN-deficient mouse embryos and gene expression was analyzed. The aim was to determine whether a lack of PDPN caused significant global changes in gene expression in primary fibroblasts. Here, we performed a microarray on WT and PDPN-deficient mouse embryonic fibroblasts to determine whether there were signficiant underlying changes in gene expression. Two replicates each of WT and PDPN KO MEFs from C57BL6/J mice

2014-10-07 | E-GEOD-62081 | biostudies-arrayexpress

Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

Project description:Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations do not respond to anti-PD-1 (L1) as well as tumors without an EGFR mutation. We showed in a xenograft mouse model of EGFR-mutated NSCLC that, neither durvalumab nor oleclumab alone inhibited tumor growth compared to the isotype control. In contrast, the combination of both antibodies significantly inhibited tumor growth and increased gene expressions that corresponded to inflammation and T cell function in tumors treated. We used microarrays to study gene expressions that corresponded to enhanced immune response in antibody-treated mice.

2022-02-23 | GSE190731 | GEO

Gene expression in WT and podoplanin (PDPN)-deficient MEFs

2014-10-07 | GSE62081 | GEO

Generation of an in vitro 3D Engineered Colorectal Cancer Patient-Derived Xenograft Model

Project description:Generation of an in vitro 3D Engineered Colorectal Cancer Patient-Derived Xenograft Model

| PRJNA634542 | ENA

Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

Project description:Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

| PRJNA788281 | ENA

WES sequencing of TRACERx NSCLC patient-derived xenograft models

Project description:WES sequencing of TRACERx NSCLC patient-derived xenograft models

| EGAS00001007364 | EGA

Gene expression data of nasopharyngeal carcinoma (NPC) cell and Podoplanin (PDPN) siRNA treatment

Project description:Podoplanin, a transmembrane sialomucin-like glycoprotein, is now widely used as a marker for lymphatic endothelial cells and fibroblastic reticular cells in lymphoid organs, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were t characterize the role of PDPN in NPC. Our results showed that PDPN was expressed in most TW01 NPC cells. PDPN knockdown by siRNA decreased NPC cell proliferation, migration, and invasion. Knocking down PDPN results in suppression of NPC cell proliferation, migration, and invasion. PDPN may serve as a potential chemotherapeutic target for NPC treatment in the future.

2019-03-19 | GSE128502 | GEO

Comparison of gene expression in xenograft tissue stably expressing ShRNA KDM1A

Project description:The purpose of this study was to chacterise the effect of KDM1A knocking down on genome-wide gene expression in human NSCLC cells in vivo. Affymetrix human transcriptome array 2.0 was used to profile the transcriptome of xenograft tumors derived from PC9 cells stably expressing either ShRNA KDM1A or ShRNA control. These cells were subcutanously injected into the right axillary of the mouse, and allowd to grow for 5 weeks to form xenograft tumors. Although KDM1A is up-regulated in NSCLC, but key genes and pathways regulated by KDM1A was not well-understood in NSCLC. Using this approach, we have shown that KDM1A repressed or activated a distinctive set of pathways and key target genes in vivo. This first comprehesive study of transciptome profile upon KDM1A koncking-down in vivo highlights the distinctive pathways regulated by KDM1A during NSCLC tumorigenesis, and it will help to identify new therapeutic targets for NSCLC treatment. Xenograft tumors derived from two cell lines: PC9 cells stably expressing ShRNA KDM1A or ShRNA control. We extracted total RNA from 3 independent xenograft tumors per cell line.

2016-07-27 | E-GEOD-71358 | biostudies-arrayexpress

Gene expression of RAW264.7 with or without Pdpn expression before and after H. pylori infection

Project description:The effect of Podoplanin (Pdpn) expression on the differential expression profile of RAW264.7 cells has been characterised in wildtype, Pdpn knockout cells and Pdpn overexpressed cells before and after H. pylori infection using 770 genes from the NanoString Mouse PanCancer Pathways Panel.

2020-05-28 | GSE151269 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data